Trial Profile
A Phase I/II Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Berzosertib (Primary) ; Topotecan (Primary)
- Indications Advanced breast cancer; Bladder cancer; Cervical cancer; Gallbladder cancer; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Rectal cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 12 Apr 2021 According to a Merck AG media release, results from this study were published in Cancer Cell.
- 12 Apr 2021 Results published in the Merck AG Media Release.